The Medical Advisor

GLP-1-based medications have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as these medicines become more widely used, another question has become increasingly important: How much of the weight lost on a GLP-1 drug comes from muscle or other lean tissue—and can that loss be minimized? The evidence shows a nuanced answer. People taking semaglutide, tirzepatide and related incretin-based medicines generally lose much more fat than lean tissue . At the same time, absolute lean mass usually falls during substantial weight loss. Importantly, lean mass is not the same thing as skeletal muscle : DXA-based “lean mass” also includes water, organs and other non-fat tissues. Therefore, a finding that lean mass decreased does not automatically mean that the same amount of skeletal muscle was lost. Recent 2026 meta-analyses suggest that roughly one-quarter to one-third of total weight lost with incretin therapy may be classified as lean ...

GLP-1-based medicines such as semaglutide and tirzepatide can cause gastrointestinal symptoms that are usually manageable, but they also carry warnings for uncommon yet potentially serious adverse events. The most useful way to understand GLP-1 safety is to separate: Emergency symptoms → seek immediate medical attention from Urgent symptoms → contact a healthcare professional promptly and seek same-day evaluation when appropriate from Common symptoms → usually monitor and manage, but discuss them if they become persistent or severe. This distinction is important because a common side effect can occasionally become medically significant when it is severe, persistent or associated with dehydration, bleeding, severe pain, breathing problems or loss of consciousness. This urgency framework is a practical patient-education tool, not an official FDA classification. The appropriate response depends on symptom severity, medical history and the specific GLP-1 medicine being used. GLP-1 Saf...

OneDayMD • The Medical Advisor A single starting point for exploring OneDayMD's health, wellness, longevity, nutrition, cancer, metabolic medicine, emerging therapies and digital-health research. Quick Answer OneDayMD is an independent health-information and research-synthesis platform covering conventional medicine, integrative health, longevity, nutrition, supplements, metabolic medicine, cancer research, emerging therapies and digital health. This Master Guide is the site's central navigation page: use it to find the right topic hub, then move from a broad guide to the specific evidence, study, therapy, supplement, condition or research question you are investigating. On this page Start Here · Core Health Hubs · Cancer & Oncology · Nutrition & Supplements · Longevity · GLP-1 & Metabolic Health · DMSO ·...